Skip to contentC
Cumberland Pharmaceuticals Inc
C
CPIXCumberland Pharmaceuticals Inc Q3 2017 · 10-Q
Revenue$11.20M$11.20M+27.4% vs Q3 2016 Net Income-$743.03K-$743.03KN/M vs Q3 2016 EPS Diluted-$0.05-$0.05N/M vs Q3 2016 Operating Income-$839,349N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Cumberland Pharmaceuticals Inc · CIK 1087294 · Engraved from SEC EDGAR
derived
Free Cash Flowderived$963,094+262.3% Margins · derivedOperating margin-7.5%−9.0 pt vs Q3 2016
Net margin-6.6%−7.8 pt vs Q3 2016
ended Sep 30, 2017 · filed Nov 8, 2017 · 39 d after period end